Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nevro (NVRO) delivered earnings and revenue surprises of 24.27% and 0.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Image source: The Motley Fool. Nevro Corp (NYSE: NVRO)Q1 2020 Earnings CallMay 5, 2020, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon and welcome to Nevro's First Quarter 2020 Conference Call.

Here's a roundup of top developments in the biotech space over the last 24 hours.On a day when the three major averages shed over 4% in reaction to bleak forecasts concerning the COVID-19 pandemic's impact, none of the Nasdaq- or NYSE-listed biotech stocks hit 52-week highs or lows.Stocks In Focus InVitae Withdraws FY20 Guidance Due To Pandemic, Plans Offering InVitae Corp (NYSE: NVTA), a medical genetics company, pre-announced first-quarter results and said it expects revenue of more than $63 million, up 55% year-over-year, billable tests of 147,000, up 65%, and non-GAAP cash burn of less than $100 million. Analysts expect revenue of $60.3 million.Citing the unknown duration and extent of COVID-19's impact on its business and the health care system in general, the company said it is withdrawing its guidance for 2020.Separately, the company announced an underwritten public offering of 17.78 million shares priced at $9 per share. All the shares are being sold by the company. The company expects the offering to close April 6 and to raise gross proceeds of about $16 million.The stock was down 11.96% at $10.31 in Thursday's premarket session. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Novartis Terminates Agreement To Sell Sandoz US Assets To Aurobindo Novartis AG (NYSE: NVS) said it has mutually agreed with Aurobindo Pharma to terminate a previously announced deal to sell the Sandoz U.S. generic oral solids and dermatology businesses to Aurobindo. The decision follows a lack of FTC approval for the transaction within anticipated timelines.Novartis shares were adding 1.57% to $82.20 in premarket trading Thursday.Nevro Forecasts Q1 Revenue Shortfall, Withdraws 2020 Guidance Nevro Corp (NYSE: NVRO) announced preliminary unaudited worldwide revenue for the first quarter of $86.4 million to $86.9 million, up from $82.1 million a year ago. This compares to the $94.96-million consensus estimate. The company attributed the potential shortfall to a rapid deceleration in March due to COVID-19 shelter-in-place policies and restrictions on elective surgical procedures.The company also withdrew its 2020 guidance issued in late February due to the rapidly evolving environment and continued uncertainties related to COVID-19.Separately, the company announced a public offering of 1.625 million shares of common stock and $165 million in aggregate principal amount of convertible senior notes due 2025.The stock fell 3.86% to $86 in after-hours trading.OpGen Closes On Curetis Purchase OpGen Inc (NASDAQ: OPGN) announced the consummation of its proposed acquisition of Dutch molecular diagnostics company Curetis N.V. OpGen shares paid as consideration for the sale will be distributed to Curetis, which will be dissolved and delisted from the Euronext exchange.OpGen shares were trading 5.44% higher at $2.52 in Thursday's premarket session. See also: The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty Eiger's HDV Study To Be Delayed, Company To Support Studies Of Peginterferon Lambda In COVID-19 Issuing an update on clinical development activity and business operations, Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) said it has taken appropriate steps to ensure the safety of patients and integrity of the HDV Phase 3 D-LIVR trial. The trial is evaluating lonafarnib and ritonavir with or without PEGylated interferon-alfa-2a in patients with chronic hepatitis D virus infection.It now expects the COVID-19 pandemic to lead to the shifting of the completion of enrollment in the study to 2021.The company also said it has begun supporting multiple investigator-sponsored studies of peginterferon lambda in COVID-19."These studies will assess a 180 mcg, once-weekly, subcutaneous dose of Lambda, and will enroll at academic centers across the U.S., as well as international sites," the company said.The shares advanced 6.27% to $6.27 in after-hours trading.Affimed's Lead Drug Gets Orphan Drug Designation In T-Cell Lymphoma Affimed NV (NASDAQ: AFMD) said the FDA has granted orphan drug designation to AFM13, its lead CD30- and CD16A-binding innate cell engager, for the treatment of patients with T-cell lymphoma.Affimed shares were up 6.92% to $1.70 in the premarket session. BioCryst Names Anthony Doyle As CFO BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) announced the appointment of Anthony Doyle as CFO. Doyle previously served as a global contract research organization's CFO.In premarket trading Thursday, BioCryst shares were adding 0.26% to $1.90.Boston Scientific Lowers Q1 Revenue Guidance Due To COVID-19 Impact Boston Scientific Corporation (NYSE: BSX) lowered its first-quarter revenue growth guidance to flat to slightly up from its previous estimate for 10-12% growth. The company attributed the predicament to a significant decline in procedural volumes in March due to COVID-19 impact.Humanigen's Lenzilumab Gets FDA Nod For Compassionate Use In COVID-19 Patients Humanigen Inc (OTC: HGEN) said the FDA approved the administration of its lenzilumab for COVID-19 patients under individual patient emergency IND applications to patients under its compassionate use program.The company said it is advancing plans to conduct a multi-center, Phase 3 study of lenzilumab for the prevention of acute respiratory distress syndrome, ARDS and/or death in hospitalized patients with pneumonia associated with coronavirus 2 infection.Applied Therapeutics Opens IND With FDA For AT-001 To Treat COVID-19-Related Lung Inflammation, Cardiomyopathy Applied Therapeutics Inc (NASDAQ: APLT) said it has opened an INDA with the FDA for AT-001 to treat acute lung inflammation and cardiomyopathy in critical COVID-19 patients. The company noted that multiple AT-001 investigator-initiated trials are now underway to address these two issues.Vir, Alnylam Expand Existing Collaboration To Include Additional Targets In COVID-19 Treatment Vir Biotechnology Inc (NASDAQ: VIR) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced an expansion of their existing collaboration for RNAi therapeutics for infectious diseases. The expansion includes up to three additional targets focused on host factors for SARS-CoV-2, including ACE2 and TMPRSS2, both of which are considered critical for viral entry.Vir shares were gaining 2.45% to $30.50 in premarket trading Thursday.Related Link: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates See more from Benzinga * 10 Biotech Winners And Losers In Q1 * The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Q4 2019 Nevro Corp Earnings Call

Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]

Q1 2020 Nevro Corp Earnings Call

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that in its patent litigation against Boston Scientific the U.S. Court of Appeals for the Federal Circuit issued a ruling in its favor. The Federal Circuit reversed the district court's indefiniteness rulings, reinstating Nevro's asserted patent claims covering methods and systems for delivering SCS therapy at high frequencies.

Q4 2018 Nevro Corp Earnings Call

Nevro (NVRO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the first quarter ended March 31, 2020 after the market closes on May 5, 2020.

Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced preliminary unaudited worldwide revenue for the quarter ended March 31, 2020 and the withdrawal of its full year 2020 financial guidance issued on February 25, 2020. In addition, the Company provided an update on the actions it is taking in response to the COVID-19 pandemic.

Nevro Corp. ("Nevro") (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the underwriter of each of Nevro's previously announced concurrent public offerings of (a) 1,625,000 shares of its common stock (the "common stock offering") and (b) $165,000,000 aggregate amount of its 2.75% convertible senior notes due 2025 (the "initial notes") (the "notes offering") has fully exercised its option to purchase an additional (a) 243,750 shares of Nevro's common stock at a public offering price of $84.00 per share, less underwriting discounts and commissions, and (b) an additional $24,750,000 aggregate amount of notes (the "additional notes" and, collectively with the initial notes, the "notes"), less underwriting discounts and commissions. Following the full exercise of the underwriter's option, Nevro anticipates selling an aggregate of 1,868,750 shares of its common stock, with total gross proceeds of approximately $157.0 million before deducting underwriting discounts and commissions and estimated offering expenses, and $189,750,000 aggregate amount of notes, before deducting underwriting discounts and commissions and estimated offering expenses. The offerings, including the common stock and additional notes that are part of the option exercise, are expected to close on April 6, 2020, subject to customary closing conditions.

Nevro (NVRO) received CE mark approval for the Senza Omnia SCS system, which is likely to boost its international presence.

Nevro Corp. ("Nevro") (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the pricing of concurrent underwritten public offerings of (a) 1,625,000 shares of its common stock at a public offering price of $84.00 per share for gross proceeds, before deducting underwriting discounts and commissions and estimated offering costs, of approximately $136,500,000 (the "common stock offering") and (b) $165,000,000 aggregate amount of its 2.75% convertible senior notes due 2025 (the "notes") (the "notes offering"). Nevro has granted the underwriters of the offerings a 30-day option to purchase an additional (a) 243,750 shares of common stock at the public offering price, less underwriting discounts and commissions and (b) $24,750,000 aggregate amount of notes, less underwriting discounts and commissions and solely to cover over-allotments with respect to the notes offering. All of the shares of common stock to be sold in the common stock offering are being offered by Nevro. The offerings of the shares and the notes are expected to close on April 6, 2020, subject to customary closing conditions.

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced it has received CE mark approval for the Senza® Omnia™ Spinal Cord Stimulation (SCS) system.

Nevro Corp. ("Nevro") (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that it has commenced a proposed underwritten public offering of 1,625,000 shares of its common stock (the "common stock offering") and $165,000,000 aggregate principal amount of its convertible senior notes due 2025 (the "notes") (the "notes offering"). All of the shares of common stock to be sold in the common stock offering will be offered by Nevro. In addition, Nevro expects to grant the underwriters of the offerings a 30-day option to purchase an additional (a) 243,750 shares of its common stock at the public offering price, less underwriting discounts and commissions and (b) $24,750,000 aggregate principal amount of the notes, less underwriting discounts and commissions and solely to cover over-allotments with respect to the notes offering. Neither the completion of the common stock offering nor the notes offering is contingent on the completion of the other. The offerings are subject to market and other conditions, and there can be no assurance as to whether or when the offerings may be completed, or as to the actual size or terms of the offerings.

Nevro's (NVRO) domestic revenues improved on a year-over-year basis in Q1.